Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología

Escobar, Carlos; Anguita, Manuel; Arrarte, Vicente; Barrios, Vivencio; Cequier, Ángel; Cosı́n-Sales, Juan; Egocheaga, Isabel; de, Esteban; Masana, L.; Pallarés, Vicente; Isla, Leopoldo Pérez de; Pintó, Xavier; González-Juanatey, José Ramón; Zamorano, José Luís

doi:10.1016/j.recesp.2019.07.024

Cited by 54 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lipid-lowering treatment (LLT) of each patient and their adherence to it was analyzed before inclusion in the study, with LDL-C levels adjusted according to Masana's correction [23], as long as the patient was correctly following the treatment. Maximal lipid-lowering therapy was defined as any LLT that reduces LDL-C levels ≥50% [24].…”

Section: Population Study and Clinical Diagnostic Criteria For Familimentioning

confidence: 99%

Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data

Sabatel-Pérez

Sánchez-Prieto

Becerra-Muñoz

et al. 2021

JCM

View full text Add to dashboard Cite

The majority of familial hypercholesterolemia index cases (FH-IC) remain underdiagnosed and undertreated because there are no well-defined strategies for the universal detection of FH. The aim of this study was to evaluate the diagnostic yield of an active screening for FH-IC based on centralized analytical data. From 2016 to 2019, a clinical screening of FH was performed on 469 subjects with severe hypercholesterolemia (low-density lipoprotein cholesterol ≥220 mg/dL), applying the Dutch Lipid Clinic Network (DLCN) criteria. All patients with a DLCN ≥ 6 were genetically tested, as were 10 patients with a DLCN of 3–5 points to compare the diagnostic yield between the two groups. FH was genetically confirmed in 57 of the 84 patients with DLCN ≥ 6, with a genetic diagnosis rate of 67.9% and an overall prevalence of 12.2% (95% confidence interval: 9.3% to 15.5%). Before inclusion in the study, only 36.8% (n = 21) of the patients with the FH mutation had been clinically diagnosed with FH; after genetic screening, FH detection increased 2.3-fold (p < 0.001). The sequential, active screening strategy for FH-IC increases the diagnostic yield for FH with a rational use of the available resources, which may facilitate the implementation of FH universal and family-based cascade screening strategies.

show abstract

Section: Population Study and Clinical Diagnostic Criteria For Familimentioning

confidence: 99%

Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data

Sabatel-Pérez

Sánchez-Prieto

Becerra-Muñoz

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Las estatinas son metabolizadas por isoenzimas del CYP450, con excepción de la pravastatina, que es metabolizada en el citosol celular. Atorvastatina, lovastatina y simvastatina sufren metabolismo de primer paso por la CYP3A4 32,33 .…”

Section: Dislipemia Y Sars-cov-2unclassified

COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?

Pallarés-Carratalá

Górriz-Zambrano²,

Ariño

et al. 2020

Medicina de Familia. SEMERGEN

View full text Add to dashboard Cite

show abstract

“…The tables show the patient distribution and mean days of follow up ( Table 2 ) and the recurring events and deaths recorded during the follow-up ( Table 3 ) by type of ASCVD (angina, AMI, ischemic stroke, TIA, and PAD) on the index date. Table 4 summarizes the use of lipid-lowering drugs at the time of enrollment in the study, classified according to the consensus document of the Spanish Society of Cardiology ( 18 ). Drug treatments account for 11% of the average cost of the follow-up of these patients; it should be noted that only 0.9% of patients received protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i).…”

Section: Resultsmentioning

confidence: 99%

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Martínez López,

Gómez Cerezo,

Gámez

et al. 2024

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

IntroductionAtherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event.MethodologyRetrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; n = 1.8 million). Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.ResultsA total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were €11,171 during the first year and €9,944 during the second year.DiscussionPatients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).

show abstract

Recomendaciones para mejorar el control lipídico. Documento de consenso de la Sociedad Española de Cardiología

Cited by 54 publications

References 30 publications

Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data

Improving Familial Hypercholesterolemia Index Case Detection: Sequential Active Screening from Centralized Analytical Data

COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Contact Info

Product

Resources

About